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Abstract
Objective
The aims of this study were to determine the prevalence of risk factors associated with
hepatocellular carcinoma (HCC) in black adult South Africans and to estimate the size of the
associated risks.
Methods
A case-control analysis of 150 black South African patients (aged 18–75 years) with HCC—
who were a subset of patients recruited for the Johannesburg Cancer Case Control Study
2000 to 2012—was undertaken. The association between this tumour and hepatitis B/C
virus infections, and human immunodeficiency virus (HIV) mono- and co-infections was
investigated. Odds ratios (ORs) and 95% confidence intervals (CI) adjusted for age, year of
diagnosis, marital status, place of birth and selected modifiable risk factors were calculated.
Results
HCC was significantly associated with a rural birthplace (p<0.05), being male and living in
an urban area for 14 years or less. The Odds Ratio (OR) for HCC increased significantly
with HBV DNA+/HBsAg+ (OR 34.5; CI:16.26–73.13), HBV DNA+/HBsAg- (OR 3.76;
CI:1.79–7.92), HBV DNA level >2000 IU/ml (OR 8.55; CI:3.00–24.54) to200,000 (OR
16.93; CI:8.65–33.13), anti-HCV (OR 8.98; CI:3.59–22.46), HBV DNA+/HIV+ co-infection
(OR 5.36; CI:2.59–11.11), but not with HBV DNA-/HIV+ (OR 0.34; CI:0.14–0.85). We did
not find a synergistic interaction between HBV and HIV. Modifiable risk factors (alcohol
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consumption, tobacco smoking, number of sexual partners, diabetes and hormonal con-
traceptive use) were nonsignificant.
Discussion
A considerable portion of the HCC burden in Johannesburg and surrounding provinces falls
on rural migrants to urban areas, most of whom are men. The HBV will continue to contrib-
ute to HCC incidence in older age-groups and in others who missed vaccination. Although
we did not find an increased risk for HCC in HIV positive individuals this may change as life
expectancy increases due to greater access to antiretroviral therapies, necessitating the
addition of hepatitis virus screening to preventive medical care.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and second leading
cause of cancer-related mortality worldwide (745,000 deaths or 9.1% of the total cancer deaths)
[1]. Approximately 80% of HCC cases occur in developing regions including sub-Saharan
Africa and southeast Asia [1], and is usually associated with poor prognosis (5-year survival of
14% from diagnosis) [2]. Surgical interventions reportedly have a high recurrence (81%) of
HCC and a low 5-year survival rate (38%) in South Africa (SA) [3].
In sub-Saharan Africa, epidemiological studies show that the most common aetiological
risk factors for HCC include hepatitis B virus (HBV), hepatitis C virus (HCV), and dietary
exposure to the fungal hepatocarcinogen aflatoxin B1 [4]. Total aflatoxin levels in SA commer-
cial foods are regulated by Section 15(1) of the Foodstuffs, Cosmetics and Disinfectants Act,
1972. Regardless of this, significant aflatoxin contamination does occur in stored crops such
as maize and groundnuts grown and stored for family or local consumption; the problem is
weather-dependent and expected to increase with increasing climate variability [5].
The World Health Organization (WHO) estimated that, in 2015, 257 million people were
infected with HBV and 70 million people with HCV, of whom 60 million and 11 million
resided in Africa, respectively [6]. In SA HBV is a well-recognized risk factor for HCC. HBV
infection is characterized by childhood acquisition via horizontal transmission, male predomi-
nance and a high prevalence in rural-born black Africans [7]. Hepatitis B vaccine, introduced
into the SA Expanded Programme on Immunisation in 1995, has been shown to effectively
control the spread of HBV in children [8].
In recent decades human immunodeficiency virus (HIV) infected persons co-infected with
hepatitis virus (HBV/HCV) have become a serious public health concern internationally due
to a significantly higher risk of HCC development [9] and mortality [10]. Most of these studies
were carried out in regions of low HBV endemicity where infections with HIV and hepatitis
B/C viruses occur at more or less the same age (sexual maturity) and are mostly limited to cer-
tain high-risk groups [11]. It is unknown whether the effects of HIV on HCC risk are the same
when it is acquired years after a chronic HBV infection is established, as is the case in sub-
Saharan African countries [12].
Thus, the aim of this study was to determine the prevalence of risk factors for HCC develop-
ment in black South African adults born prior to the introduction of routine HBV vaccination
in 1995, as part of the Expanded Programme on Immunisation [8]. These factors included
both viral factors (HBV/HCV; HIV) and potentially modifiable risk factors including alcohol
consumption, tobacco smoking, self-reported diabetes and hormonal contraception use.
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Materials and methods
Study design and setting
This retrospective analysis consisted of a subset of participants enrolled in the Johannesburg
Cancer Case Control Study (JCCCS), a study that recruited self-identified black African (not
mixed ancestry) cancer patients in the greater Johannesburg, Gauteng province, public referral
hospitals that offer oncology services. Prior to commencement of cancer treatment, a written
or witnessed verbal consent was obtained for interview and for having blood drawn for future
assessment of factors of interest. Face to face interviews were conducted by trained research
nurses who assigned a study number to participants. Each participant also gave consent to
have records reviewed by the research nurses who collected the required information for the
cancer diagnosis confirmation. Blood specimens were independently anonymously tested for
HIV infection and stored at the National Health Laboratory Service as previously described
[13]. All patient information provided to researchers was only identified by the study number.
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval granted by the University of the Witwatersrand Human Research
Ethics Committee (Medical) (M150239; M140271).
Eligibility criteria
Newly diagnosed with primary HCC (ICD-O: 8170/3 and ICD10: C22), with no prior history
of any cancer, was enrolled from 1 September 2000 to 31 December 2012. A total of 158 HCC
cases, all with available stored pretreatment serum, were included. Fifty-one (34%) were con-
firmed by histology, 31 (20.7%) by cytology, 57 (38%) by elevated alpha fetoprotein levels
(>450 ng/ml) and/or ultrasound (4) or CT scan (1), with the remaining cases (7.3%) con-
firmed as HCC by physicians. In the time period of the analysis only 8 potential HCC cases
were excluded: 4 because patient files for confirmation of diagnosis could not be located, 3
because only a discharge or transfer letter indicating the HCC diagnosis was available, and 1
because the tumour was a secondary cancer.
For each HCC case three matched controls were randomly selected from the JCCCS data-
base, matched by recruitment hospital, sex, and age at the time of interview (± 3 years). Follow-
ing previously published criteria controls were included on the basis of confirmed malignant
neoplasms that are not known to have a possible infectious cause [14]. Cancers with ill-
defined, secondary and unspecified sites of carcinoma were also excluded. Twelve (2.7%)
potential controls could not be used because sera were depleted.
It is highly unlikely that any of the participants were vaccinated against HBV because all
participants were born prior to 1995, the year HBV vaccination, at 6, 10 and 14 weeks of age
was introduced into the South African Expanded Programmed on Immunisation [8].
Laboratory testing
Enzyme-linked immunosorbent assay kits were used to test for serological markers of anti-
HBc (Murex1 Anti-HBc Total, Abbott Diagnostics, UK) and anti-HCV (Murex anti-HCV
4.0 ELISA, Abbott Diagnostics, UK). All HBV-DNA positive samples were tested for HBsAg
(Murex HBsAg v3.0, Abbott Diagnostics, UK), and all HBsAg-positive further tested for
HBeAg (ETI-EBK PLUS; DiaSorin).
HBV-DNA was extracted from 200 μl of serum using a QIAamp1 DNA Blood Mini Kit
(Qiagen, Germany), according to the manufacturer’s instructions. HBV-DNA detection and
quantification were performed as described previously [15]. Briefly, quantitative real-time
PCR (RT-PCR) was performed in a 25 μl total volume using 12.5μl of 2X EagleTaq Universal
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Master Mix with ROX (Roche Applied Science, Basel, Switzerland), 10 μM HBV-Taq1 for-
ward primer, 10μM HBV-Taq2, 10 μM BS-1 probe and 2 μl of DNA. Thermal cycling was
performed in a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Inc., Hercules,
CA) as follows: 1 cycle of 2 min at 50˚C and 10 min at 95˚C, followed by 45 cycles of 95˚C
for 15 sec and 60˚C for 1 min. HBV-DNA concentration was calculated using a standard of
cloned plasmid full-genome HBV-DNA, with concentrations ranging from 5x102 to 5x107
IU/ml. Calibration of this standard was confirmed by comparison with an World Health
Organization (WHO) International HBV-DNA Standard (product code 97/750 NIBSC;
Hertfordshire, UK). The averaged copies/ml value was divided by 4.7 to convert copies/ml to
IU/ml, with a detection limit of ~20 IU/ml or 94 copies/ml [16]. The blank, positive controls,
negative controls, and samples were all tested in duplicate; the standard curve samples were
tested in triplicate.
Risk factor classification
Modifiable risk factors—alcohol consumption, tobacco smoking and hormonal contraceptive
use—included in this study have been previously described [17, 18]. Briefly, current smokers,
including those who had stopped smoking within 5 years of date of interview, were classified
according to the daily number of cigarettes smoked, and were subdivided into light (1–14 g/
day) and heavy (15 g/day) smokers. Those who stopped smoking more than 5 years prior to
the date of interview were classified as former smokers. Current alcohol drinkers were subdi-
vided into categories based on the frequency of alcohol consumed per week assuming 1 serving
of an alcoholic beverage contains 10g of ethanol: non-drinkers (<1 drink/week); moderate
drinkers (1–7 drinks/week for women, 1–14 drinks/week for men; heavy drinkers– 8 or
more drinks/week or 4 or more drinks in a single occasion for women, 15 or more drinks/
week or 5 or more drinks in a single occasion for men [19]. HBV-DNA levels were divided
into HBV-DNA categories according to the South African guidelines for the management of
chronic HBV infection [20]. Occult HBV infection (OBI) was characterised by the presence of
HBV-DNA in HBsAg-negative individuals with or without serological markers of HBV infec-
tion [21]. Use of antiretroviral therapy (ART) was only included in the questionnaire from
November 2004; thus this information was excluded from analysis.
Statistical analyses
Continuous variables such as the age of participants were summarized as means (standard
deviation); HBV-DNA levels (>20 IU/mL) were summarized as medians (interquartile range).
Chi-square and Fisher’s exact (for sparse data) were used to evaluate differences among and
between the case and the control groups. The Shapiro-Wilk test was used to test for normal
distribution of quantitative values. All non-normal distributions were analysed with the
Mann-Whitney test. Conditional logistic regression models were used to evaluate the impact
of independent predictors of the outcome as odds ratios (OR) with 95% confidence intervals
(CI) and assessment of potential confounding factors including sex, age group, country and
province of birth, number of years lived in urban area (0–14, 15–29 and30 years), place of
birth (urban or rural), alcohol consumption, HIV status and anti-HCV positivity. Adjustment
of other potential HCC confounders, including marital status, smoking, self-reported diabetes,
hormonal contraception use and the number of lifetime sexual partners, did not significantly
change the estimates significantly and were therefore not included in the model. Statistical sig-
nificance was defined as p-value<0.05. All analysis was done using STATA software, version
13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP).
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Results
Table 1 shows the demographic characteristics and viral infection status of the HCC and con-
trol participants. The majority of participants were born in SA (88.9%) and close to two thirds
were born outside the Gauteng Province (60.4%). HCC cases were more likely to be male
(74%) and rural-born (65.3%, p = 0.03). The male-to-female ratio was higher for the rural-
born (4.2:1) than urban-born participants (1.6:1), and in the older population (>40 years old)
born in rural areas (5:1), compared to their younger counterparts (40 years old) (3:1). In con-
trast, urban-born HCC cases reported a more equal male-to-female ratio in the two age groups
(1.5:1 and 1.7:1 for>40 and40 years old, respectively). The difference between the HCC
cases and controls in terms of the number of years recently lived in an urban environment was
also statistically significant, with approximately half of all HCC cases (48%) having lived in an
urban area for only 0–14 years, compared to about a third of controls (34.9%, p = 0.01). The
prevalence of HBV DNA and anti-HCV antibodies was significantly higher in HCC cases than
in the controls (p<0.001), while HIV-positivity did not differ statistically between the groups
(18.7% vs 25.8%, p = 0.08).
Of all the 588 participants, 315 (53.6%) were anti-HBc-positive and 136 (23.1%) were HBV
DNA-positive (14.1% and 8.8% of HBV DNA-positive were HBsAg-positive HBsAg-negative,
respectively). Of the 150 HCC cases, HBsAg positivity was significantly higher in men than in
women (77.5% vs 22.5%, respectively). HBsAg- and HBeAg-positivity was significantly differ-
ent between HCC cases and controls (HBsAg: 41.3% and 4.8%, respectively, p<0.001; HBeAg:
12% and 0.9%, respectively, p<0.05). Table 2 suggests that the increase in the risk for HCC
was associated with some combination of HBV markers—anti-HBc, HBV-DNA and/or
HBsAg. The multivariate analysis of HBV markers did not meaningfully differ from those
observed in univariate analysis. Relative to those who tested negative for all markers, the risk
for HCC among HBV DNA-positive participants who were HBsAg-positive or HBsAg-nega-
tive, was estimated at OR 34.48 (95% CI: 16.26–73.13) and OR 3.76 (95% CI: 1.79–7.92)
respectively, with or without detectable anti-HBc. The risk was highest when all three HBV
markers (HBsAg, HBV DNA and anti-HBc) were present (OR 46.71, 95% CI: 21.00–103.90).
To investigate the relationship between HBV-DNA levels and HCC development partici-
pants were divided into HBV-DNA categories according to the South African guidelines for
the management of chronic HBV infection [20] and as shown in Table 3. Of the 150 HCC
cases, 80 (53.3%) had detectable levels of serum HBV-DNA, of which 68 (85%) had HBV-DNA
levels20,000 and less than 200,000 IU/mL and 41 (51.3%) had greater than or equal to
200,000 IU/mL. Comparable levels in the control participants accounted for 12.8%, 62.5% and
37.5%. An increasing trend in OR was noted with increasing viremia, and was statistically sig-
nificant from2000 IU/mL (OR 8.55, 95% CI: 3.00–24.54) to200,000 IU/mL (OR 16.93,
95% CI: 8.65–33.13) (Table 3).
Table 4 shows the independent and combined effect of HBV and/or HCV, with and without
the presence of HIV infection. The excess estimated OR, as risk for HCC development, in indi-
viduals with HBV-DNA positivity and HIV infection did not exceed the sum of the relative
excess risks for each risk factor alone: 5.36< (9.09–1.00) + (0.39–1.00). Using our data HBV/
HIV co-infection has little effect on risk for the development of HCC. As few HCC and control
participants were anti-HCV-positive, the joint effect of HCV with HBV and/or HIV could not
be accurately estimated. Irrespective of HBV serological markers HCV-positive participants
from the current study were, on average, close to 20 years older than those who were anti-
HCV negative (61.9 vs 44.9 years) whereas HBsAg-positive participants were approximately 10
years younger than those who were HBsAg-negative (39.4 vs 46.7 years). HIV-positive HCC
cases were significantly older than the HIV-positive controls (43.3 vs. 38.1 years, respectively,
Risk factors of HCC in SA
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Table 1. Demographic and virological characteristics: HCC cases and age- and sex-matched control participants from the Johannesburg Cancer Case Control
Study, 2000 to 2012.
Characteristic Total HCC Control p-value
N (%) N (%) N (%)
Age 0.97
18–29 65 (11.1) 15 (10.0) 50 (11.4)
30–39 150 (25.5) 37 (24.7) 113 (25.8)
40–49 142 (24.1) 37 (24.7) 105 (24.0)
50–59 120 (20.4) 33 (22.0) 87 (19.9)
 60 111 (18.9) 28 (18.7) 83 (18.9)
Missing Data 0 (0.0) 0 (0.0) 0 (0.0)
mean (SD) 45.8±13.3 46.1±13.3 45.7±13.3
Sex 1.00
Female 153 (26.0) 39 (26.0) 114 (26.0)
Male 435 (74.0) 111 (74.0) 324 (74.0)
Missing Data 0 (0.0) 0 (0.0) 0 (0.0)
Year of Interview 0.51
2000–2004 192 (32.7) 48 (32.0) 144 (32.9)
2005–2008 194 (33.0) 45 (30.0) 149 (34.0)
2009–2012 202 (34.4) 57 (38.0) 145 (33.1)
Missing Data 0 (0.0) 0 (0.0) 0 (0.0)
Marital Status 0.37
Married/living as married 362 (61.6) 99 (60.0) 263 (60.0)
Separated 60 (10.2) 10 (6.7) 50 (11.4)
Single/ Never Married 111 (18.9) 28 (18.7) 83 (18.9)
Widowed 53 (9.0) 13 (8.7) 40 (9.1)
Missing Data 2 (0.3) 0 (0.0) 2 (0.5)
Country of Birth <0.001
Outside South Africa 65 (11.1) 29 (19.3) 36 (8.2)
South Africa 523 (88.9) 121 (80.7) 402 (91.8)
Missing Data 0 (0.0) 0 (0.0) 0 (0.0)
Province of Birth 0.21
Gauteng 207 (39.8) 42 (28.0) 165 (37.7)
Other Provinces 316 (60.4) 79 (52.7) 237 (54.1)
Missing Data 0 (0.0) 0 (0.0) 0 (0.0)
Place of Birth 0.03
Rural 346 (57.7) 98 (65.3) 241 (55.2)
Urban 253 (42.2) 52 (34.7) 196 (44.9)
Missing Data 1 (0.2) 0 (0.0) 1 (0.2)
Place of Residence 0.15
Rural 55 (9.4) 11 (7.3) 44 (10.0)
Urban 532 (90.5) 138 (92.0) 394 (90.0)
Missing Data 1 (0.2) 1 (0.7) 0 (0.0)
Years lived in Urban 0.01
0–14 years 225 (38.3) 72 (48.0) 153 (34.9)
15–29 years 113 (19.2) 27 (18.0) 86 (19.6)
30 years 247 (42.0) 50 (33.3) 197 (45.0)
Missing Data 3 (0.5) 1 (0.7) 2 (0.5)
HIV Status 0.08
(Continued)
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p = 0.01). Of the 39 HIV-positive individuals with detectable HBV-DNA, 25 (64.1%) were
HBsAg-positive and 14 (35.9%) were HBsAg-negative (p = 0.69). HBV-DNA levels were sig-
nificantly higher in HBV-HIV co-infected participants, compared to HBV mono-infected—
median [IQR] log10 titre: 6.4 (5.5–7.3) vs 5.3 (4.9–6.7), respectively (p = 0.007).
Table 1. (Continued)
Characteristic Total HCC Control p-value
N (%) N (%) N (%)
Positive 141 (24) 28 (18.7) 113 (25.8)
Negative 447 (76) 122 (81.3) 325 (74.2)
Missing Data 0 (0.0) 0 (0.0) 0 (0.0)
HBV DNA Status <0.001
Positive 136 (23.1) 80 (53.3) 56 (12.8)
Negative 452 (76.9) 70 (46.7) 382 (87.2)
Missing Data 0 (0.0) 0 (0.0) 0 (0.0)
Anti-HCV Status <0.001
Positive 32 (5.4) 19 (12.7) 13 (3.0)
Negative 550 (93.5) 131 (87.3) 419 (95.7)
Missing Data 6 (1.0) 0 (0.0) 6 (1.4)
https://doi.org/10.1371/journal.pone.0196057.t001
Table 2. Hepatitis B viral markers and the associated odds ratio (OR) for HCC in black South Africans, 2000–2012.
No. Anti-HBc HBV DNA HBsAg HCC (N = 150) (%) Controls (N = 437) (%) OR (95% CI)
1 - - - 27 (18.0) 207 (47.4) 1.00
2 + - - 43 (28.7) 175 (40.1) 1.59 (0.90–2.81)
3 - + - 6 (4.0) 18 (4.1) 2.60 (0.90–7.53)
4 ± + - 18 (12.0) 34 (7.8) 3.76 (1.79–7.92)
5 + + - 12 (8.0) 16 (3.7) 5.10 (2.06–12.62)
6 - + + 7 (4.7) 7 (1.6) 10.19 (2.99–34.75)
7 ± + + 62 (41.3) 21 (4.8) 34.48 (16.26–73.13)
8 + + + 55 (36.7) 14 (3.2) 46.71 (21.00–103.90)
 Adjusted for sex, age group, country and province of birth, number of years lived in urban area, place of birth, alcohol consumption, HIV status and anti-HCV
positivity. Occult HBV infection is shown in rows 3–5. Hepatitis B viral marker status -: Negative; +: Positive; ±: Positive and/or Negative.
https://doi.org/10.1371/journal.pone.0196057.t002
Table 3. Hepatitis B virus DNA levels and the associated odds ratio (OR) for HCC in black South Africans: 2000–2012.
HBV DNA Levels (IU/ml) HCC (%) Control (%) OR (95% CI) OR (95% CI)
200,000 41 (27.3) 21 (4.8) 10.65 (5.94–19.11) 16.93 (8.65–33.13)
20,000–199,999 27 (18.0) 14 (3.2) 10.52 (5.26–21.07) 10.97 (5.20–23.14)
2000–19,999 10 (6.7) 8 (1.8) 6.82 (2.60–17.89) 8.55 (3.00–24.54)
200–1999 1 (0.7) 12 (2.7) 0.45 (0.06–3.55) 0.68 (0.08–5.68)
<200 1 (0.7) 1 (0.2) 5.46 (0.34–88.27) 1.54 (0.08–28.22)
Undetected 70 (46.7) 382 (87.2) 1.00 1.00
 Adjusted for sex, age group, country and province of birth, number of years lived in urban area, place of birth, alcohol consumption, HIV status and anti-HCV
positivity. P value <0.001.
https://doi.org/10.1371/journal.pone.0196057.t003
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No tested modifiable risk factors showed statistically significant differences between HCC
and control groups; approximately half of the HCC participants were non-alcohol drinkers
(51.3%) and 47.3% were non-tobacco smokers (Table 5).
Discussion
Almost a decade has elapsed since the most recent investigation of risk factors for and demo-
graphics of HCC in SA [22]. Consistent with previous hospital-based case-controls studies
[22–26], we found a mean age of 46 years and a predominance of men in the HCC cases.
Although our results show a higher prevalence of previous exposure to HBV in rural-born
than in urban-born HCC cases (65% vs 35%, p<0.001), when compared to an earlier study
in the 1980s [26], the lack of statistical significance in HBsAg positivity between rural- and
urban-born cases was consistent (p = 0.3). Thus, HCC participants born in urban environ-
ments are just as likely to have been infected with HBV during early childhood as those who
were born and in rural areas and subsequently moved to an urban area [27]. Although not
investigated in the present study, it is possible that those born in rural areas are also vulnerable
to co-carcinogens prevalent in rural settings, such as dietary exposure to aflatoxin B1 and iron
Table 4. Main effect of HBV-DNA positivity and interactive effects with anti-HCV- and/or HIV-positivity on the risk for HCC in black South Africans, 2000–2012.
Characteristics All Participants HCC Control p-value OR (95% CI)
N (%) N (%) N (%)
HBV DNA and anti-HCV <0.001
HBV DNA-/HCV- 421 (72.3) 52 (34.7) 369 (84.2) 1.00
HBV DNA+/HCV- 129 (22.2) 79 (52.7) 50 (11.4) 11.56 (7.10–18.85)
HBV DNA-/HCV+ 28 (4.8) 18 (12.0) 10 (2.3) 10.60 (4.33–26.00)
HBV DNA+/HCV+ 4 (0.7) 1 (0.7) 3 (0.7) 3.15 (0.31–32.40)
Missing 6 (1.0) 0 (0.0) 6 (1.4)
HBV DNA and HIV <0.001
HBV DNA-/HIV- 350 (59.5) 62 (41.3) 288 (65.8) 1.00
HBV DNA+/HIV- 97 (16.5) 60 (40.0) 37 (8.5) 9.09 (5.27–15.66)
HBV DNA-/HIV+ 102 (17.3) 8 (5.3) 94 (21.5) 0.39 (0.17–0.89)
HBV DNA+/HIV+ 39 (6.6) 20 (13.3) 19 (4.3) 5.36 (2.59–11.11)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Anti-HCV and HIV <0.001
Anti-HCV-/HIV- 412 (70.1) 105 (70.0) 307 (70.1) 1.00
Anti-HCV+/HIV- 29 (4.9) 17 (11.3) 12 (2.7) 6.47 (2.69–15.59)
Anti-HCV-/HIV+ 138 (23.5) 26 (17.3) 112 (25.6) 0.48 (0.27–0.85)
Anti-HCV+/HIV+ 3 (0.5) 2 (1.3) 1 (0.2) 3.69 (0.28–48.36)
Missing 6 (1.0) 0 (0.0) 6 (1.4)
HBV DNA, anti-HCV and HIV <0.001
No Infection 321 (55.2) 46 (30.7) 275 (63.6) 1.00
HBV DNA only 91 (15.6) 59 (39.3) 32 (7.4) 10.29 (5.90–17.97)
Anti-HCV only 26 (4.5) 16 (10.7) 10 (2.3) 8.98 (3.59–22.46)
HIV only 100 (17.2) 6 (4.0) 94 (21.8) 0.34 (0.14–0.85)
2 or more infection 44 (7.6) 23 (15.3) 21 (4.9) 5.99 (2.99–11.97)
Missing 6 (1.0) 0 (0.0) 6 (1.4)
Adjusted for sex, age group, country and province of birth, number of years lived in urban area, place of birth, alcohol consumption, HBV DNA, HIV status and anti-
HCV positivity
https://doi.org/10.1371/journal.pone.0196057.t004
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overload [28, 29]. When they leave the rural areas for urban environments, their exposure to
these co-carcinogens may decrease, thereby delaying the progression of HCC [27].
HBsAg prevalence in our study as a whole (14%) and in the HCC participants (41%), are in
agreement with the prevalence found in the general SA population (from 8% to 10%) [30] and
in HCC patients from previous SA case-controls studies (ranging from 40.3% to 70%) [27, 30–
32]. Our study shows that in black South Africans HBV infection continues to be a primary
risk factor for HCC development, followed by HCV infection. Our risk estimates for HBsAg
(OR 34.5) and anti-HCV (OR 9.0) are consistent with a study of HCC patients attending a
rural hospital in Mpumalanga, SA (OR 33.2 for HBsAg) [31], but are somewhat higher than
another study conducted in urban Johannesburg hospitals (OR 23.3 for HBsAg and 6.6 for
anti-HCV) [32]. The synergistic effect of HBV-HCV co-infection for risk of developing HCC
observed by Kew et al. [32], was not found in the current analysis (Table 4), possibly because
very few participants were infected with both viruses (Table 4).
To the best of our knowledge the current study is the first to determine an association
between HCC risk and the 2000 IU/mL threshold of HBV-DNA levels in black South Africans,
as well as the increased risk of HCC with increasing HBV-DNA level, in a dose-response
relationship (Table 3). We found only one prior study that estimated HCC risk related to
HBV-DNA viral load in SA: among 124 HBsAg-positive cases and 125 asymptomatic carriers
Table 5. Modifiable risk factor characteristics of HCC cases and of control participants and the associated odds ratio (OR) in black South Africans, 2000–2012.
Characteristics HCC Control p-value OR (95% CI) OR (95% CI)
N (%) N (%)
Alcohol Use 0.73
Non-drinkers 77 (51.3) 225 (51.4) 1.00 1.00
Moderate 46 (30.7) 145 (33.1) 0.93 (0.61–1.41) 1.24 (0.73–1.10)
Heavy 27(18.0) 68 (15.5) 1.16 (0.69–1.94) 1.22 (0.64–2.30)
Missing Data 0 (0.0) 0 (0.0)
Tobacco Smoking 0.30
Non-smokers 71 (47.3) 215 (49.1) 1.00 1.00
Former-smokers 46 (30.7) 121 (27.6) 1.25 (0.74–2.12) 1.63 (0.81–3.29)
Current (1-14g/day) 7 (4.7) 39 (8.9) 1.15 (0.75–1.77) 1.63 (0.85–4.21)
Current (15 g/day) 26 (17.3) 63 (14.4) 0.54 (0.23–1.27) 0.62 (0.21–1.89)
Missing Data 0 (0.0) 0 (0.0)
Diabetes(self-reported) 0.51
Negative 145 (96.7) 415 (94.7) 1.00 1.00
Positive 5 (3.3) 23 (5.3) 0.62 (0.23–1.67) 0.83 (0.28–2.50)
Missing Data 0 (0.0) 0 (0.0)
No. of Lifetime Sexual Partners 0.57
0–1 17 (11.3) 48 (11.0) 1.00 1.00
2–5 80 (53.3) 216 (49.3) 1.05 (0.57–1.92) 0.97 (0.46–2.01)
6+ 49 (32.7) 165 (37.7) 0.84 (0.44–1.59) 0.81 (0.36–1.82)
Missing Data 4 (2.7) 9 (2.1)
Hormonal Contraception Use (women only) 0.09
Never oral or injectable contraceptive user 13 (8.7) 41 (9.4) 1.00 1.00
Ever Oral and/or injectable contraceptive user 25 (16.0) 73 (16.7) 1.08 (0.50–2.34) 1.09 (0.43–2.79)
Missing Data 1 (0.7) 0 (0.0)
 Adjusted for sex, age group, country and province of birth, number of years lived in urban area, place of birth, alcohol consumption, HBV DNA, HIV status and anti-
HCV positivity
https://doi.org/10.1371/journal.pone.0196057.t005
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identified in a cohort of black southern Africans, the reported geometric mean viral loads were
553,618 copies/ml (approximately 118,000 IU/mL) and 16,084 copies/ml (approximately 3,400
IU/mL), respectively [22]. In the current study the risk of developing HCC in individuals with
low HBV-DNA levels (<2000 IU/mL) was not significant, and differed in comparison to ear-
lier studies conducted in Korea [33] and The Gambia [34] where five- and three-times higher
respective risks were reported. This discrepancy, observed at low HBV-DNA levels, may
result from marked differences in population characteristics and HBV genotypes both of
which may influence the viral load. Moreover, environmental risk factors in West Africa such
as aflatoxin B1[35]—which is classified as a human carcinogen by IARC (International Agency
for Research on Cancer)—may play an important role, especially at low viral loads. In the
1980s aflatoxin contamination in SA commercial foodstuffs was shown to be low (0.66 μg/kg)
in comparison to Mozambique (range from 0.7–6.43 μg/kg) [36]; this was also confirmed in a
more recent study (2004) that reported low rates of mycotoxin contamination in staple foods
such as maize [37]. In any case suppression of HBV, even if only for a finite period, may
significantly reduce risk for developing HCC [38]. Long-term follow-up studies are needed to
further determine the role of low HBV-DNA levels as a risk factor for HCC in black South
Africans.
In the current study, although the HIV prevalence in the case (18.7%) and control (25.8%)
groups did not differ significantly (p = 0.08), both groups were higher than the background
HIV seropositivity in this adult population in Gauteng province, SA (12.4%) [39]. Further-
more, we did not find an increased risk of developing HCC in relation to HIV infection (OR
0.4). This is consistent with an earlier case-control study from SA in the 1990s, that recruited
913 black African HIV cases and 325 controls comprised of patients with cancers other than
those known to have an infectious cause (OR 0.9, 95% CI:0.3–2.9) [14]. Although it has been
suggested that HIV infection accelerates liver damage related to HBV infection [40], a possible
explanation for our finding a lack of higher HCC risk in HIV-positive individuals might be
the reduction in the continual inflammation related to immune-mediated clearance of HBV-
infected hepatocytes [41] as a result of impaired innate and adaptive immune response in
HIV-coinfection [42]. Additionally, given the long induction period of HCC, many South
African HIV-infected patients, in the absence of ART, died earlier, before symptoms related
to HBV could manifest and in contrast to evidence from developed countries [43, 44]. Millions
of relatively young HIV-infected SA adults are now surviving longer as a result of the wide-
spread rollout of ART which began in 2009 [45] and is now available free of charge to all HIV
infected people, regardless of CD4 count [46]. This may or may not be associated with a paral-
lel increase in the burden of HCC depending on the coverage of infant HBV vaccination, the
possible spread of HCV and also an increased prevalence of modifiable risk factors [47]. The
shift in cancer burden from AIDS-defining cancers to non-AIDS defining cancers seen in
developed countries is not yet evident in SA but is likely to occur in time [48]. Although both
HIV and HBV are endemic in SA systematic studies investigating the association between
HBV-HIV coinfection and HCC have not been done. This may reflect under-ascertainment
and reporting due to the often late presentation with cancer, especially in resource-limiting
settings thus further highlighting the need for a systematic approach to surveillance for HCC
in the HIV-positive population in SA [4, 48].
OBI prevalence found in the HCC cases (12%) was significantly less than that found by an
earlier SA study (48.4%) [25] but translated to a four-times higher risk of HCC (Table 2). Our
findings show that OBI is associated with increased HCC risk (Table 2), and the highest OR of
5.10 (95% CI: 2.06–12.62) in OBI-infected participants with anti-HBc positivity was consistent
with a previous meta-analysis of retrospective studies (OR 6.08, 95% CI: 3.45–10.72) [49].
Although the clinical implications of OBI are not clearly understood, this condition has been
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extensively reported in HIV-infected ART-naïve patients in SA, with a prevalence ranging
from 15.1% to 23% [16, 50], higher than that found in the current study (8.8%). The differences
may be influenced by the ART use. Although OBI did not differ between HIV-positive and
negative individuals in this study (9.9% vs 8.5%, p = 0.238), the presence of OBI poses a
unique challenge in managing HBV disease, particularly against a backdrop of the high HIV
prevalence in the general SA population (12% or 7 million are HIV-positive) (http://aidsinfo.
unaids.org). Future research is required to determine the true risk of acquiring OBI as it is not
detected by conventional HBsAg testing.
This study has limitations. Modifiable risk factors were self-reported, there was limited
data on the prior use of antiretroviral treatment, absence of HIV viral and CD4 count, and an
absence of sufficient clinical data evaluating liver function and/or the presence of cirrhosis, all
of which may have influenced the estimates of HCC risk. Additionally, no aflatoxin exposure
or HCV virological data were available. Using sera following prolonged storage could poten-
tially introduce errors as a result of protein or HBV-DNA degradation. However, this possible
effect was minimized by selecting control participants that were matched by time and hospital
to the HCC cases enrolled. While the use of sonography in detecting HCC has its limitations
[51], only four included cases were diagnosed by this method alone. In limited-resource set-
tings HCC patients often present at an advanced stage where the finding of a mass using imag-
ing techniques is rarely confirmed by histological examination [52].
A considerable proportion of HCC burden in northern SA is being borne by rural migrants
to urban areas, the majority of whom are working-age men who may have had exposure to co-
carcinogens prevalent in the rural environment. HBV-induced HCC will continue to occur
in the older population group and in immigrants, and may increase in the foreseeable future
especially when HIV co-infected individuals have an extended lifespan due to ART therapy,
thus allowing sufficient time for HCC to develop [53]. Given the overburdened public health
services in SA, the challenge is to put in place preventative measures through health education
and early detection and screening programs targeting high risk individuals residing in rural
areas. Poverty alleviation and the provision of cost-effective medical care will also assist in
HCC treatment and in incidence reduction.
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